Trial · NCT00623974
Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia
NCT00623974, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2010-09-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia. Trials, record NCT00623974. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00623974
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia
- NCT number
- NCT00623974
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Hypocalcemia
- Interventions
- Teriparatide (Forteo), Calcium, Calcitriol
- First posted
- 2008-02-26
- Last updated
- 2012-12-06
- Results first posted
- 2010-09-13
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients With Success | 2 - 7 days post-treatment | A patient "success" is defined as a normal calcium level (Ca\>=8 and Ca\<= 10.5) within 48 hours post-treatment initiation and a normal Ca level maintained through day 7 post-treatment initiation. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients With Success | 2 - 7 days post-treatment | Terminated due low accrual, none of 7 participants met eligibility criteria therefore not treated nor randomized to study arms. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Calcium + Calcitriol | 0 | |
| Overall Study | STARTED | Teriparatide 20 Mcg | 0 | |
| Overall Study | STARTED | Teriparatide 40 Mcg | 0 | |
| Overall Study | STARTED | Teriparatide 60 Mcg | 0 | |
| Overall Study | COMPLETED | Calcium + Calcitriol | 0 | |
| Overall Study | COMPLETED | Teriparatide 20 Mcg | 0 | |
| Overall Study | COMPLETED | Teriparatide 40 Mcg | 0 | |
| Overall Study | COMPLETED | Teriparatide 60 Mcg | 0 | |
| Overall Study | NOT COMPLETED | Calcium + Calcitriol | 0 | |
| Overall Study | NOT COMPLETED | Teriparatide 20 Mcg | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Calcium + Calcitriol | ||
| Total, all-cause mortality | Teriparatide 20 Mcg | ||
| Total, all-cause mortality | Teriparatide 40 Mcg | ||
| Total, all-cause mortality | Teriparatide 60 Mcg | ||
| Total, other adverse events | Calcium + Calcitriol | 0 | 0 |
| Total, other adverse events | Teriparatide 20 Mcg | 0 | 0 |
| Total, other adverse events | Teriparatide 40 Mcg | 0 | 0 |
| Total, other adverse events | Teriparatide 60 Mcg | 0 | 0 |
| Total, serious adverse events | Calcium + Calcitriol | 0 | 0 |
| Total, serious adverse events | Teriparatide 20 Mcg | 0 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00623974
GET https://conductscience.org/api/trials/v1/NCT00623974/registered